Slow-cycling cancer cells may explain why breast cancer returns decades later Written byBree Foster, PhD

Slow-cycling cancer cells may explain why breast cancer returns decades later Researchers identify a slow-cycling, therapy-tolerant state in breast cancer cells linked to Rac1 signaling and late metastatic relapse. Written byBree Foster, PhD https://www.drugdiscoverynews.com/slow-cycling-cancer-cells-may-explain-why-breast-cancer-returns-decades-later-17171 A new study has uncovered a previously underappreciated mechanism that may help explain why estrogen receptor-positive (ER+) breast cancer can return years — or even decades — after patients are declared cancer-free.

Women, power and cancer: from Commission to collective action Weds, May 20, 2026 16:00 - 17:30 CEST

https://iarc2026conf.iarc.who.int/en/programme/partners-sessions/28?utm_campaign=conferencealerts&utm_medium=email&_hsenc=p2ANqtz-93Jtrb3X1iC0oBEFxHgT4JGvDc1VZ6ghJPGToVE4cXOM9r-2YsKHtFrUKJ-lg4jujAaZ34tZyrpUsUIK5iTNDVT7VPIg&_hsmi=416559897&utm_content=416559897&utm_source=hs_email Executive summary Women interact with cancer in complex ways, as healthy individuals participating in cancer prevention, as patients, as health professionals, researchers, policymakers, and as unpaid caregivers. In all these domains, women often are subject to overlapping forms of discrimination, such as due to age, race, ethnicity and socio-economic status, that render them structurally marginalized. These myriad factors can restrict a woman’s rights and opportunities to avoid cancer risks, are a barrier to diagnosis and quality cancer care, maintain an unpaid caregiver workforce that is predominantly female, and hinder women’s professional advancement. The Lancet Commission on women, power and cancer was created to address urgent questions at the intersection of social inequality, cancer risk, and outcomes, and the status of women in society. https://www.thelancet.com/do-content/women-power-and-cancer-lancet-commission?dgcid=hubspot_email_conferencealerts_iarc26_lancetwomenpowercancer23&utm_campaign=conferencealerts&utm_medium=email&_hsenc=p2ANqtz-_J48TcsLLek7UXqvUMllEXgWEWSSDXtwJu456UuZimJ9j0pbJaLaQXnRtrH0Z_RC8yfJt41RDUqxvm4kNCc7v0XOe9SA&_hsmi=416559897&utm_content=416559897&utm_source=hs_email

Clinical Perspectives on the Use of PI3K/AKT Pathway Inhibitors in the Management of HR+/HER2− Metastatic Breast Cancer Authors: Peter Schmid, MD, PhD, FRCP; Kevin Kalinsky, MD, MS, FASCO; Frédérique Penault-Llorca, MD, PhD

https://www.medscape.org/viewarticle/clinical-perspectives-use-pi3k-akt-pathway-inhibitors-2026a100087h?page=1&src=mkmcmr_driv_stan_mscpedu_260512-OUS-HONC-clinical-perspectives-use-pi3k-akt-pathway-inhibitors-2026a100087h-cta&uac=148436CN

Early-Onset Colorectal Cancer Risk Factors Identified in Two Studies Damian McNamara, MA May 13, 2026 ++ ++ + + +

Early-Onset Colorectal Cancer Risk Factors Identified in Two Studies Damian McNamara, MA https://www.medscape.com/viewarticle/early-onset-colorectal-cancer-risk-factors-identified-two-2026a1000ffn May 13, 2026 https://www.medscape.com/c25/p14/digestive-disease-week-ddw-2026-2026a1000c5k Did Hyperglycemia Affect Inavolisib-Efficacy in Patients With Breast Cancer? Megan Brooks https://www.medscape.com/viewarticle/did-hyperglycemia-affect-inavolisib-efficacy-patients-breast-2026a1000fgf May 13, 2026 Efficacy outcomes were numerically higher among patients who experienced inavolisib-associated hyperglycemia, in a post hoc exploratory analysis of the INAVO120 trial. That trial found that patients with PIK3CA-mutated, hormone receptor (HR)-positive, HER2-negative advanced breast cancer benefitted from the addition of inavolisib to standard palbociclib and fulvestrant. https://www.medscape.com/c25/p14/esmo-breast-cancer-2026-2026a1000c6q Obesity Drugs Linked to Lower Cancer Risk Edited by Archita Rai https://www.medscape.com/viewarticle/obesity-drugs-linked-lower-cancer-risk-2026a1000fgc May 13, 2026 Only 1 in 4 Eligible Adults Receive Lung Screening Kelsey Mesmer https://www.medscape.com/viewarticle/only-1-4-eligible-adults-receive-lung-screening-2026a1000fee May 13, 2026 Low PSA Alone May Not Fully Predict Survival in Advanced Prostate Cancer Edited by Victoria Stern https://www.medscape.com/viewarticle/low-psa-alone-may-not-fully-predict-survival-advanced-2026a1000few May 13, 2026

The Ivermectin Paradox in Oncology: When a Grain of Science Becomes a ‘Miracle Cure’ Myth Arturo Loaiza-Bonilla, MD, MSEd May 12, 2026

https://www.medscape.com/viewarticle/ivermectin-paradox-oncology-when-grain-science-becomes-2026a1000dyq I’ve started to recognize the cadence of the question before it’s fully asked. A patient or caregiver leans in — often after a long visit about scans, side effects, and the thousand small logistics that cancer demands — and says something like, “Doctor, can I ask you about ivermectin? I heard it’s a cancer cure. If it might help, why wouldn’t we try it?”

Medscape Now! The Changing Demographics of Colorectal Cancer Authors: ​Naseem Bazargan, MPH

https://www.medscape.org/viewarticle/medscape-now-changing-demographics-colorectal-cancer-2026a1000at2?page=1 Colorectal cancer (CRC) ranks as the second most common cause of cancer-related death in the United States, with 158,850 new cases and 55,230 deaths anticipated in 2026.[1] While the overall age-standardized incidence of CRC has declined by approximately 46% from its peak of 66.2 per 100,000 in 1985 to 35.5 per 100,000 in 2019, driven largely by screening uptake and modifiable risk factor reduction, this progress masks a generational divergence.[1,2] Namely, incidence has continued to fall by 2.5% annually among adults aged 65 years and older, while incidence among adults aged 20 to 49 years has increased by approximately 3% annually.[3] Among those aged 50 to 64 years, rates have been stable or rising modestly (+0.4% annually).

Scientists create detailed map of odor receptors

Scientists create detailed map of odor receptors At a Glance Researchers used genetic techniques to map more than 1,000 odor-detecting receptors in mice, revealing a previously unrecognized organizational structure that’s responsible for the sense of smell. The findings could lead to new therapeutic approaches for people who have lost their sense of smell. https://www.nih.gov/news-events/nih-research-matters/scientists-create-detailed-map-odor-receptors